Navigation Links
Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy
Date:7/11/2014

onset seizures.

In February 2009, Eisai Europe Limited, a European subsidiary of Eisai Co., Ltd. (Eisai), entered into a license and co-promotion agreement with BIAL, which gave the rights to Eisai to sell eslicarbazepine acetate under the trade name Zebinix® in Europe. Zebinix® was approved by the European Commission on April 21, 2009 as adjunctive therapy in adult patients with partial-onset seizures with or without secondary generalization and is currently marketed in Europe under the agreement.

About Sunovion Pharmaceuticals Canada Inc.
Sunovion Pharmaceuticals Canada Inc. is focused on the development and commercialization of prescription products in Canada. In addition to commercializing Sunovion Pharmaceuticals Inc.'s products, our strategy is to license pharmaceutical products that meet the needs of patients and the Canadian health care system, currently focusing on cardiovascular disease, infectious disease and central nervous system (CNS) disorders.  More information about Sunovion Pharmaceuticals Canada Inc. is available at www.sunovion.ca.

Sunovion Pharmaceuticals Canada Inc., a subsidiary of the U.S. based Sunovion Pharmaceuticals Inc., is headquartered in Mississauga, Ontario.  Sunovion Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is headquartered in Marlborough, Mass.  More information about Sunovion Pharmaceuticals Inc. is available at www.sunovion.com.

About Sumitomo Dainippon Pharma Co., Ltd. 
Sumitomo Dainippon Pharma is a top-ten listed pharmaceutical company in Japan with a diverse portfolio of pharmaceutical, animal health and food and specialty products. Sumitomo Dainippon Pharma aims to pro
'/>"/>

SOURCE Sunovion Pharmaceuticals Canada Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders
2. Collaborations, FDA Approvals, Appointments, Patents, and Stock Movements - Research Report on Aetna, United Therapeutics, Perrigo, Arena Pharmaceuticals, and Keryx Biopharmaceuticals
3. Shimadzu’s New Aggregates Sizer Aggregation Analysis System for Biopharmaceuticals Enables Real-time Quantitative Analysis
4. Savient Receives Approval From Bankruptcy Court To Sell Substantially All Assets To Crealta Pharmaceuticals
5. Biotech Briefing: Advancing Biotechs Forging Ahead With Breaking News Developments: Alliqua, OncoMed Pharmaceuticals, EnteroMedics, Unilife, Amarin
6. Vanda Pharmaceuticals to Present at the 25th Annual Piper Jaffray Healthcare Conference
7. Actinium Pharmaceuticals Announces 2013 Annual Shareholder Meeting
8. Avanir Pharmaceuticals to Participate in Two Conferences in December
9. Jazz Pharmaceuticals Announces Participation at the Piper Jaffray Healthcare Conference on December 3
10. RXi Pharmaceuticals Reports Financial Results for the Third Quarter of 2013
11. RXi Pharmaceuticals Announces the Start of Their First Phase 2 Study with RXI-109 for Treatment of Hypertrophic Scars in Conjunction with Scar Revision Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... , ... Inc. Magazine released its annual list of the 5,000 fastest-growing privately ... for the three years through 2014. Being named to the Inc. 5000 list designates ... country. , “We are thrilled to make the Inc. 5000 list for 2015,” ...
(Date:8/27/2015)... ... 27, 2015 , ... Proove Biosciences, a commercial and ... of genetics and hypertension at the International Academy of Cardiology Annual ... Canada. The event, which boasts an extensive overview of the latest research developments ...
(Date:8/26/2015)... 26, 2015  Roka Bioscience, Inc. (NASDAQ: ROKA ... testing solutions for the detection of foodborne pathogens, today ... the Sidoti & Company Emerging Growth Conference on September ... at the New York Marriott Marquis. ... through the investor relations section of Roka Bioscience,s website ...
(Date:8/26/2015)... Aug. 26, 2015  Platform therapeutic company Symic ... received a $1.5M Phase II SBIR grant from ... develop its therapeutic agent to reduce arteriovenous fistula ... end stage renal disease (ESRD) patients undergoing hemodialysis. ... of Diabetes and Digestive and Kidney Diseases (NIDDK), ...
Breaking Biology Technology:iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3
... Webcast and Conference Call Scheduled for Tuesday, May 13th at ... Therapeutics, Inc.,(Nasdaq: IMRX ) today announced that the Company ... 13, 2008, at 5:00 p.m. ET to discuss,first quarter 2008 ... ImaRx,s corporate website at, http://www.imarx.com and will be archived ...
... DIEGO, May 7 Arena Pharmaceuticals, Inc.,(Nasdaq: ARNA ... ended,March 31, 2008., Total revenues in the first ... in the first quarter of 2007, and included $2.0 ... Ltd,and $0.6 million in patent reimbursements from Arena,s collaborations ...
... augment Quintiles Consulting offerings, RESEARCH TRIANGLE ... today announced that it has signed an ... and market research,consulting firm located in Boston ... The acquisition of Eidetics will strengthen ...
Cached Biology Technology:Arena Pharmaceuticals Announces First Quarter 2008 Financial Results 2Arena Pharmaceuticals Announces First Quarter 2008 Financial Results 3Arena Pharmaceuticals Announces First Quarter 2008 Financial Results 4Arena Pharmaceuticals Announces First Quarter 2008 Financial Results 5Arena Pharmaceuticals Announces First Quarter 2008 Financial Results 6Arena Pharmaceuticals Announces First Quarter 2008 Financial Results 7Arena Pharmaceuticals Announces First Quarter 2008 Financial Results 8Quintiles Signs Agreement to Acquire Eidetics 2
(Date:8/20/2015)... ., Aug. 20, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market ... has joined The Smart Card Alliance and the EMV ... Alliance and the Smart Card Alliance Latin America (SCALA) ... industry peers and thought leaders promoting adoption of smart ...
(Date:8/12/2015)... , Aug. 12, 2015   MedNet Solutions ... the entire spectrum of clinical research, is proud to ... the company,s comprehensive SaaS-based eClinical technology platform, has led ... the first two quarters of 2015.   Q2 2015 ... largest quarters measured by contract value sold in the ...
(Date:8/10/2015)... Germany , August 10, 2015 ... in Eye Tracking Technology for more than two decades, ... Platform for integration into all consumer display formats. The ... seamless integration of eye tracking into consumer tablets, laptops, ... reality smart glasses. Omnivision,s leading sensor technology contributes to ...
Breaking Biology News(10 mins):NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4MedNet Solutions Experiences Explosive Corporate Growth 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3
... in the August 30 issue of Nature provides, ... the relationship between the carbon cycle and climate processes over ... the Earth is known to have transitioned from "hothouse" to ... the carbonate compensation depth, or CCD. Defined as the depth ...
... conservation measures must account for the complexity of the ... different spatial and temporal scales. "Scale-sensitive research" emerges as ... adjust concepts, analyses, and tools to the scale in ... must ensure that the decisions they take resolve ecological ...
... role in successful foraging for southern elephant seals, a ... the open access journal PLOS ONE ., The ... the diving behaviour of four female southern elephant seals ... with light detectors. The researchers found that increased bioluminescence ...
Cached Biology News:New Nature study illuminates 55 million years of the carbon cycle and climate history 2New Nature study illuminates 55 million years of the carbon cycle and climate history 3Scientists call policy-makers to be scale-aware 2Scientists call policy-makers to be scale-aware 3
... ACS Reagent Grade C 19 H 9 ... 691.95 PRODUCT SPECIFICATIONS Form: Powder Clarity of ... pH 3.0 - Yellow pH 4.6 ... dye in agarose and acrylamide gel electrophoresis. ...
tracking dye in electrophoresis; free acid, C 19 H 10 BrO 5 S; MW: 669.96...
Denhardt's Solution is a mixture of blocking agents used in membrane-based hybridization protocols. The solution contains 1% Ficoll (type 400) 1% polyvinylpyrrolidone and 1% bovine serum albumin. Ste...
... CHEMICONs ELF 97 Cytological Labeling Kit provides ... the detection of cellular targets, including cell-surface ... Cytological Labeling Kit contains the patented ELF ... fluorescent yellow-green precipitate at the site of ...
Biology Products: